Clinical Trials Arena on MSN

ImmunityBio’s Anktiva shows success as combo treatment in NSCLC

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

ImmunityBio announces results from Anktiva clinical program

ImmunityBio (IBRX) announced results from its Anktiva clinical program in non-small cell lung cancer based on two studies, ...

Study Reveals Method to Restore 'Exhausted' Blood Stem Cells

CINCINNATI, Jan. 13, 2026 /PRNewswire/ -- In a groundbreaking proof-of-concept study, researchers at Cincinnati Children's report success at restoring healthy function to blood-making stem cells that ...
Stocktwits on MSN

IBRX garners retail attention on positive update in immunotherapy for lung cancer patients

The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lun…

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
Medindia

Can a Blood Test Detect Depression or Suicide Risk?

High immune inflammation detected through simple blood tests is tied to a 57% higher risk of depression and a 56% higher risk ...